🔗 Share this article

While America continues making historic revisions to its vaccination guidelines, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on coronavirus shots during the pandemic and has focused upon possible deaths after COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials planned to reveal radical revisions to the pediatric vaccine schedule in December, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of alignment with many the international standard with insufficient data for improved outcomes. The planned update has been pushed back until the next year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood shot schedules in the US to become more in line with Denmark, a country with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

So far statements, she has continued to focus on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious experience in drug development, approval processes or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a large organization. She is not an expert in drug approvals.”

Previous commissioners of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she stated.

“Many people just focuses on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There’s a biosimilars program, OTC medication office and more, and all of those have to be supervised,” Dr. Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major leadership aspect to the position, which manages more than 5,000 employees. “It’s a huge leadership role, if you do it right,” Woodcock added.

Official Statement and Contentious Policies

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment represents increased cooperation among agency officials on immunizations, a press secretary responded that the “questions are based on flawed presumptions”.

“Her resume matches the duties of her job,” the representative said, noting the months Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the agency head's new fast-track approval initiative, a disputed one-day medication authorization process that reportedly concerned her preceding directors. “How are these therapies being picked for this expedited pathway? Who makes the decisions?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

Overall, he said, “the agency seems to be moving towards less stringent regulations of most medications, aside from immunizations.”

Established Track Record on Immunizations

With immunizations, Dr. Høeg has a clearer, if problematic, track record, critics have noted. She published a analysis using unverified public submissions to assess the frequency of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the new government encompassed altering rules for new vaccines and halting “unnecessary” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has according to sources floated the idea of excluding teenage boys from receiving Covid vaccinations.

“She’s an all-around dogmatist who commences with her preconceived notions and reverse-engineers to fit the data in a highly disingenuous, fraudulent manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|